AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02504125
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of normal saline intravenously approximately 15 minutes before incision
Trial: NCT04496999
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
Trial: NCT03671109
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
Trial: NCT00771251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
Trial: NCT04336748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01714843
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01318590
Drug: EUS procedure with drug injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
Trial: NCT01073228
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01073228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03382301
Drug: Ciclosporin A preconditioning before renal artery stenosis dilation
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
Trial: NCT03382301
Drug: NaCl preconditioning before renal artery stenosis dilation
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
Trial: NCT00778609
Drug: EV/DNG (Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
Trial: NCT00778609
Drug: Encapsulated Microgynon + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
Trial: NCT02533557
Drug: lidocaine mixed with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
Trial: NCT01868555
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Trial: NCT00549666
Drug: Placebo 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40 mg once daily during treatment period
Trial: NCT02263248
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
Trial: NCT04599725
Drug: medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical abortion
Trial: NCT02228304
Drug: Eylea® injected intravitreally administered every 8 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
Trial: NCT00672386
Drug: JNJ16269110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg twice daily for 12 weeks
Trial: NCT00672386
Drug: JNJ16269110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg twice daily for 12 weeks
Trial: NCT00672386
Drug: JNJ16269110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg twice daily for 12 weeks
Trial: NCT00672386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 12 weeks
Trial: NCT01291147
Drug: Levobupivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivicaine 0.5% continous infusion for 48 hours
Trial: NCT02551523
Drug: Standard of care combinational antiretroviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03319784
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
Trial: NCT04111159
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
Trial: NCT00000379
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00259922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02123615
Drug: Adverse Reactions of Gammagard subcutaneously at Week 12
RxNorm normalized name: Gammagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Trial: NCT04193501
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
Trial: NCT02209012
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levulan PDT given in CP0108
Trial: NCT02123615
Drug: Adverse Reactions of Gammagard subcutaneously at Week 24
RxNorm normalized name: Gammagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Trial: NCT02123615
Drug: Adverse Reactions of Gammagard subcutaneously at Week 36
RxNorm normalized name: Gammagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Trial: NCT02123615
Drug: Adverse Reactions of Gammagard subdermally at Week 12
RxNorm normalized name: Gammagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
Trial: NCT02123615
Drug: Adverse Reactions of Gammagard subdermally at Week 24
RxNorm normalized name: Gammagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Trial: NCT02123615
Drug: Adverse Reactions of Gammagard subdermally at Week 36
RxNorm normalized name: Gammagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Trial: NCT01846221
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
Trial: NCT02920541
Drug: S 055746
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
Trial: NCT01609166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream application in the other side of the body, twice a day for 6 months
Trial: NCT01947491
Drug: Comp01 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02128425
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients
Trial: NCT02128425
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Trial: NCT03320850
Drug: Placebo and Hydrogel admixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation
Trial: NCT00327743
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, twice daily, Day 1-Day 14 of a 21-day cycle
Trial: NCT03091881
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos will be given 10 min before spinal block
Trial: NCT02031640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02091375
Drug: GWP42003-P 20 mg/kg/day Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Trial: NCT02205008
Drug: adjuvant systemic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)
Trial: NCT01755702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01755702
Drug: Experimental paracetamol + caffeine formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental paracetamol + caffeine formulation
Trial: NCT01755702
Drug: ibuprofen marketed formulation
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen marketed formulation
Trial: NCT01755702
Drug: Paracetamol marketed formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol marketed formulation
Trial: NCT00448890
Drug: GSK729327
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00448890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK729327 Matching placebo - Tablets
Trial: NCT01747538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00571701
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar appearing capsules containing inert ingredients
Trial: NCT03540875
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Trial: NCT03228524
Drug: D-Aspartate
RxNorm normalized name: D-Aspartate oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
Trial: NCT03228524
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03676296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
Trial: NCT04033341
Drug: LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04033341
Drug: [14C]-LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02184585
Drug: Treatment sequence A
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
Trial: NCT02184585
Drug: Treatment sequence B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
Trial: NCT02184585
Drug: Treatment sequence C
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
Trial: NCT01329809
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
Trial: NCT01128101
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
Trial: NCT01238640
Drug: Code STD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Single-dose of experimental nicotine product coded STD
Trial: NCT01238640
Drug: Code STE
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg Single-dose of experimental nicotine product coded STE
Trial: NCT01238640
Drug: Nicorette Microtab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A comparative 2 mg Single-dose of marketed tablet
Trial: NCT03596281
Drug: pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 or 20 or 30 mg/m² Q3W IV
Trial: NCT01205126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Trial: NCT00768755
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Trial: NCT02662764
Drug: Zalviso™ 15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
Trial: NCT03700333
Drug: S-1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).
Trial: NCT01250535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po, once a day, days 1 through 14
Trial: NCT01250535
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg, po, once a day, days 1 through 14
Trial: NCT02565719
Drug: REP 2139-Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REP 2139-Mg = magnesium chelate complex of REP 2139
Trial: NCT02565719
Drug: REP 2165-Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REP 2165-Mg = magnesium chelate complex of REP 2165
Trial: NCT02445404
Drug: fractionated ICED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
Trial: NCT04323306
Drug: MMV688533
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational medicinal product
Trial: NCT00855595
Drug: Doxycycline (Oracea)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received systemic doxycycline 40 mg once daily for 12 week
Trial: NCT00089778
Drug: Fibroblast growth factor 5 (FGF-5):172-176/217-220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
Trial: NCT00372710
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02149823
Drug: Syntocinon 24 Intranasal Units (IU)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02149823
Drug: Syntocinon 40 Intranasal Units (IU)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02149823
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01380717
Drug: Beta-blocker, ACE-inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
Trial: NCT04525079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching CT-P59
Trial: NCT04555096
Drug: GC4419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 Minute IV Infusion
Trial: NCT04555096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 Minute IV Infusion
Trial: NCT02050815
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02815865
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone 3 mg will be inserted to the posterior fornix
Trial: NCT00851513
Drug: Depmedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local steroids
Trial: NCT01772199
Drug: GSK239512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
Trial: NCT00723099
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01772199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to almost white, round tablets. Once daily orally.
Trial: NCT02100670
Drug: 1% diclofenac sodium plus 3% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be applied four times daily for 10 days.
Trial: NCT02100670
Drug: 1% diclofenac sodium plus 0.09% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be applied four times daily for 10 days.
Trial: NCT04322006
Drug: TJ004309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody to CD73
Trial: NCT01121302
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
Trial: NCT01121302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00571766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 g twice a day for 14 weeks
Trial: NCT03224221
Drug: fluorouracil and platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
Trial: NCT01040390
Drug: Lappa Arctium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
Trial: NCT00405457
Drug: Restasis, Optive Tears
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restasis and Optive Tears use twice daily more frequently if needed
Trial: NCT02131818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be received placebo 2 capsules orally bid pc for 5 days
Trial: NCT01144676
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.